The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
BRCA
PD-L1
TMB
early stage
high-grade serous ovarian carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
09
05
2023
revised:
25
06
2023
accepted:
28
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression,
Identifiants
pubmed: 37446361
pii: ijms241311183
doi: 10.3390/ijms241311183
pmc: PMC10342764
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI19/01331
Organisme : Instituto de Salud Carlos III
ID : PI22/01892
Organisme : Instituto de Salud Carlos III
ID : PMP22/00054
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00316
Organisme : Spanish Ovarian Cancer Research Group
ID : NA
Organisme : Asociación Española Contra el Cáncer
ID : NA
Références
Front Oncol. 2021 Feb 01;10:572203
pubmed: 33634012
Gynecol Oncol. 2016 Jan;140(1):42-7
pubmed: 26556769
Int J Gynecol Cancer. 2022 Jan;32(1):48-54
pubmed: 32522775
PLoS One. 2013 Nov 14;8(11):e80063
pubmed: 24244610
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Gynecol Oncol. 2019 Jun;153(3):562-567
pubmed: 30948193
Clin Cancer Res. 2015 Feb 1;21(3):652-7
pubmed: 25398451
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Front Genet. 2022 Jan 11;12:688207
pubmed: 35087563
Am J Surg Pathol. 2020 May;44(5):649-656
pubmed: 32294063
Gynecol Oncol. 2019 May;153(2):217-222
pubmed: 30803719
Virchows Arch. 2012 Mar;460(3):237-49
pubmed: 22322322
Int J Gynecol Pathol. 2020 Nov;39(6):558-566
pubmed: 31851060
Int Immunopharmacol. 2017 Nov;52:7-14
pubmed: 28846888
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Genome Med. 2018 Oct 31;10(1):81
pubmed: 30382883
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
BMC Genomics. 2022 Jan 13;23(1):51
pubmed: 35026984
BMC Cancer. 2018 Mar 27;18(1):347
pubmed: 29587661
JCO Precis Oncol. 2020 Jun 16;4:
pubmed: 32923884
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
JAMA. 2012 Jan 25;307(4):382-90
pubmed: 22274685
Am J Surg Pathol. 2020 Jul;44(7):982-990
pubmed: 32384322
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707805
Ann Oncol. 2014 Jun;25(6):1165-71
pubmed: 24631948
Am J Surg Pathol. 2020 Feb;44(2):149-161
pubmed: 31498173
Am J Surg Pathol. 2016 Mar;40(3):302-12
pubmed: 26551621
Am J Surg Pathol. 2020 Aug;44(8):1050-1060
pubmed: 32384321
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Sci Rep. 2021 Jan 11;11(1):387
pubmed: 33432021
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Gynecol Oncol. 2022 Aug;166(2):263-268
pubmed: 35667901
Int J Gynecol Pathol. 2016 Sep;35(5):430-41
pubmed: 26974996
Virchows Arch. 2020 Jul;477(1):83-91
pubmed: 31980961
Nature. 2022 Dec;612(7941):778-786
pubmed: 36517593
Clin Cancer Res. 2022 Jul 1;28(13):2911-2922
pubmed: 35398881
Cancer Med. 2019 Jul;8(8):3928-3935
pubmed: 31124283
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35101941
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
EJC Suppl. 2020 Aug 22;15:1-15
pubmed: 33240438
Mod Pathol. 2012 Apr;25(4):625-36
pubmed: 22193042
Hum Pathol. 2018 Oct;80:11-27
pubmed: 29944973
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920967241
pubmed: 33193829